中山为什么一大便就会带血中山大便硬就出血,中山治疗痔疮医院有哪些,中山为什么大便后有血,中山痔疮哪医院好,中山华都胃肠医院,中山治痔疮多钱,中山女 便血

BEIJING, May 11 (Xinhuanet) -- New retirees suddenly confronted with plenty of time on their hands might be happy to learn that reading keeps one mentally alert and abreast of current aff airs, says Ursula Lenz of Germany's working group of senior citizens' organizations, BAGSO.Growing old can present difficulties such as failing eyesight or problems concentrating, but experts encourage the elderly not to give up on reading and to adapt to their situation.From the perspective of health professionals, there are many advantages to reading books or newspapers for senior citizens.Reading helps the elderly keep a sharp mind. The ability to transform words into mental images is good for cognitive performance. Reading also improves vocabulary, language use and the ability to concentrate, according to Simone Helck from the Kuratorium Deutsche Altershilfe, an organization in Germany that helps promote and develop strategies for taking care of the elderly.So, what exactly happens in the brain when we read?"The brain builds new synapses, junctions between the neurons, when it's stimulated such as during reading," says Manfred Gogol, a physician and president of Germany's Society for Gerontology and Geriatrics.Gogol recommends reading books that deal with subjects that are of special interest to the reader. If a long novel seems like too much work, then try a novella or collection of short stories.But a prerequisite for reading is that any sight defect is corrected by an optician.In response to the needs of elderly people, publishers print books with large typefaces and bigger line spacing. Lenz says it is worthwhile asking for large print books in libraries and bookshops.But no matter what the reading matter is, another important aspect is being able to exchange opinions about a book with other people. Whether it's a society magazine, highbrow literature or a daily newspaper, there is always something to talk about.

DAVOS, Switzerland, Jan. 28 (Xinhua) -- China and Switzerland formally launched bilateral talks on a free trade agreement Friday.Speaking at the opening ceremony, Chinese Commerce Minister Cheng Deming said the agreement talks between China and Switzerland have attracted huge attention and interest from the countries' leadership and business communities.Cheng expected a successful conclusion of the FTA negotiations. Cheng said a free trade agreement would enhance mutual trust between the two sides and promote economic development and closer ties between China and Switzerland.Swiss Federal Councilor Johann Schneider-Ammann expressed similar aspirations for the agreement as did his Chinese counterpart."The free trade agreement would further enhance trade and investment relations on a mutually beneficial basis, but also create many new opportunities for close exchange and cooperation," Schneider-Ammann said.China and Switzerland have seen fast-growing bilateral trade and investments for decade. In the past 10 years, China's exports to Switzerland have grown by 18 percent while Switzerland registered an even stronger 25 percent surge in exports to China.Currently, China is the largest trading partner of Switzerland in Asia, while Switzerland ranks ninth among China's trading partners in Europe.The Chinese commerce minister is leading a delegation at Davos to attend the World Economic Forum, which started Wednesday.

WASHINGTON, April 6 (Xinhua) -- A study led by researchers at the University of Michigan (U-M) showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppresser function. This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53."For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer," says lead study author Shaomeng Wang, director of the Cancer Drug Discovery Program at the U-M Comprehensive Cancer Center.Wang presented the study Wednesday at the American Association for Cancer Research 102nd annual meeting.Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects. These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study, which was done in collaboration with Ascenta Therapeutics and Sanonfi-Aventis, researchers showed that these new drugs shrank tumors without significant side effects.Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer. Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.

WASHINGTON, March 24 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Thursday approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.In the United States shingles affects approximately 200,000 healthy people between the ages of 50 and 59, per year. It is a disease caused by the varicella-zoster virus, which is a virus in the herpes family and the same virus that causes chickenpox.After an attack of chickenpox, the virus lies dormant in certain nerves in the body. For reasons that are not fully understood, the virus can reappear in the form of shingles, more commonly in people with weakened immune systems and with aging."The likelihood of shingles increases with age. The availability of Zostavax to a younger age group provides an additional opportunity to prevent this often painful and debilitating disease" said Karen Midthun, director of FDA's Center for Biologics Evaluation and Research, in a statement. ( Shingles is characterized by a rash of blisters, which generally develop in a band on one side of the body and can cause severe pain that may last for weeks, and in some people, for months or years after the episode.Approval was based on a multicenter study conducted in the United States and four other countries in approximately 22,000 people who were 50-59 years of age. Half received Zostavax and half received a placebo. Study participants were then monitored for at least one year to see if they developed shingles. Compared with placebo, Zostavax reduced the risk of developing shingles by approximately 70 percent.The most common side effects observed in the study were redness, pain and swelling at the site of injection, and headache, according to the FDA.Zostavax, manufactured by Merck & Co., was originally approved on May 26, 2006, for the prevention of shingles in individuals 60 years of age and older.